Sunovion Pharmaceuticals Inc., an NEC member, recently announced the promising results of their Phase 2/3 study for drug candidate Dasotraline, which showed significant improvement of Attention Deficit Hyperactivity Disorder (AHDH) symptoms in children 6-12 years old.
Dasotraline is a new chemical discovered by Sunovion that inhibits dopamine and norepinephrine reuptake. The drug has an extended half-life that allows it to steadily provide the therapeutic effects over a 24-hour period. Sunovion is studying the drug to determine its use in treating ADHD in children and adults, as well as Binge Eating Disorder in adults. Upon completion of the current studies and talks with the U.S. Food and Drug Administration (FDA), Sunovion plans to submit a New Drug Application for Dasotraline to treat ADHD in children and adults to the FDA in 2017.
“Sunovion is dedicated to advancing the treatment of serious neuropsychiatric conditions, such as ADHD,” said Antony Loebel, M.D., Sunovion’s Executive Vice President and Chief Medical Officer.
The New England Council congratulates Sunovion on the promising results of the Dasotraline study. Read more in Sunovion’s press release and Pharmaceutical Business Review.
04/20/2021 | Read Post
04/20/2021 | Read Post
04/1/2021 | Read Press Release
03/9/2021 | Read Press Release